Clinical trial
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute…
NCT00442221 · POZEN, Industry · Completed
Key facts
| NCT number | NCT00442221 |
|---|---|
| Title | The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months |
| Official title | An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months |
| Lead sponsor | POZEN, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine Headaches |
| Intervention type | Drug |
| Interventions | Sumatriptan and Naproxen sodium |
| Enrollment | 500 |
| Start date | May 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Mar 1, 2007 |
| Last update posted | Mar 1, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: